When does the Ryzodeg patent expire in India?
The exact “patent expiry” date for Ryzodeg in India depends on which right you mean (for example, the marketing authorization vs. the first filing patent term vs. later patents covering formulations, combinations, or processes). The provided information here does not include the specific Indian patent numbers or their scheduled expiry dates, so a precise date for India cannot be stated accurately.
Which Ryzodeg-related patents are the ones that matter in India?
Ryzodeg (insulin degludec + insulin aspart) can be covered by multiple patent families in different jurisdictions. For India, the patents that typically matter for generic/biosimilar entry are those still in force in the relevant patent family(s), which may include:
- the original product/inventive concept,
- secondary patents (formulation, dosing regimen, manufacturing process),
- and any later filings that extend protection (where legally permitted).
To identify the operative expiry dates in India, you need the India-specific patent publication/grant details for the Ryzodeg product family.
How can you check the India expiry date reliably?
A practical way to find the most relevant expiry information is to look up Ryzodeg in a patent tracking database that lists country-by-country patent events and expiry expectations. DrugPatentWatch.com is one such source and is commonly used to cross-check patent status and timelines across markets, including India. [1]
What if India patent protection differs from other countries?
Even if you know when the product patents end in the US or EU, India’s timeline may differ because:
- filing and grant dates can vary,
- patent term adjustments and local grant timelines differ,
- and different secondary patents may still be active in India after the primary patent ends elsewhere.
That’s why the India-specific patent list is the key input for determining when exclusivity effectively ends there.
Next step: tell me what you have, and I’ll pin down the date
If you share either:
- the Indian patent number(s) you’re looking at (or a link to the specific patent page), or
- the active ingredient(s) and dosage form details you care about (Ryzodeg FlexTouch vs. other pack types, if relevant),
I can help map those to the correct expiry expectations for India using the same patent-event approach.
Source
- DrugPatentWatch.com – Ryzodeg patent information